Tumor Lysis Syndrome with CD20 Monoclonal Antibodies for Chronic Lymphocytic Leukemia: Signals from the FDA Adverse Event Reporting System

Diagnosis and Treatment of Chronic Lymphocytic Leukemia

(2023) Mazyar Shadman   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Direct Cell Death Induced by CD20 Monoclonal Antibodies on B Cell Lymphoma Cells Revealed by New Protocols of Analysis

(2023) Michael Constantinides et al.   Cancers

Impulse Control Disorders by Dopamine Partial Agonists: A Pharmacovigilance-Pharmacodynamic Assessment through the FDA Adverse Event Reporting System

(2022) Michele Fusaroli et al.   INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY

Adrenal Insufficiency with Anticancer Tyrosine Kinase Inhibitors Targeting Vascular Endothelial Growth Factor Receptor: Analysis of the FDA Adverse Event Reporting System

(2022) Emanuel Raschi et al.   Cancers

Detection algorithms and attentive points of safety signal using spontaneous reporting systems as a clinical data source

(2021) Yoshihiro Noguchi et al.   BRIEFINGS IN BIOINFORMATICS

Chronic lymphocytic leukemia: 2022 update on diagnostic and therapeutic procedures

(2021) Michael Hallek et al.   AMERICAN JOURNAL OF HEMATOLOGY

Tumour lysis syndrome in patients with chronic lymphocytic leukaemia treated with BCL-2 inhibitors: risk factors, prophylaxis, and treatment recommendations

(2020) Francesco Paolo Tambaro et al.   Lancet Haematology

Lessons to be Learnt from Real-World Studies on Immune-Related Adverse Events with Checkpoint Inhibitors: A Clinical Perspective from Pharmacovigilance

(2020) Emanuel Raschi et al.   Targeted Oncology

Case–non-case studies: Principle, methods, bias and interpretation

(2019) Jean-Luc Faillie   THERAPIE

Evaluation of the Expression Time of Ganciclovir-Induced Adverse Events Using JADER and FAERS

(2019) Go Ando et al.   BIOLOGICAL & PHARMACEUTICAL BULLETIN

Prevention and Management of Tumor Lysis Syndrome in Patients with CLL and Coexisting Conditions Treated with Venetoclax-Obinutuzumab or Chlorambucil-Obinutuzumab: Results from the Randomized CLL14 Trial

(2019) Othman Al-Sawaf et al.   BLOOD

Causality Assessment of Olfactory and Gustatory Dysfunction Associated with Intranasal Fluticasone Propionate: Application of the Bradford Hill Criteria

(2018) Chandrashekhar S. Muganurmath et al.   ADVANCES IN THERAPY

iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL

(2018) Michael Hallek et al.   BLOOD

Past, Present, and Future of Rituximab—The World’s First Oncology Monoclonal Antibody Therapy

(2018) Timothy M. Pierpont et al.   Frontiers in Oncology

Tumor Lysis Syndrome

(2018) Shelly M. Williams et al.   ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE

Tumor Lysis Syndrome in Chronic Lymphocytic Leukemia with Novel Targeted Agents

(2017) Bruce D. Cheson et al.   ONCOLOGIST

Tumor lysis syndrome in the era of novel and targeted agents in patients with hematologic malignancies: a systematic review

(2016) Scott C. Howard et al.   ANNALS OF HEMATOLOGY

Data mining differential clinical outcomes associated with drug regimens using adverse event reporting data

(2016) Mayur Sarangdhar et al.   NATURE BIOTECHNOLOGY

The Tumor Lysis Syndrome

(2011) Scott C. Howard et al.   NEW ENGLAND JOURNAL OF MEDICINE

Shrinkage observed-to-expected ratios for robust and transparent large-scale pattern discovery

(2011) G Niklas Norén et al.   STATISTICAL METHODS IN MEDICAL RESEARCH